--- title: "Acadia Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 307.96 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294871588.md" datetime: "2026-08-04T20:56:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294871588.md) - [en](https://longbridge.com/en/news/294871588.md) - [zh-HK](https://longbridge.com/zh-HK/news/294871588.md) generator: "portal-rs" --- # Acadia Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 307.96 M Revenue: As of FY2026 Q2, the actual value is USD 307.96 M, beating the estimate of USD 295.52 M. EPS: As of FY2026 Q2, the actual value is USD 0.18, beating the estimate of USD 0.0699. EBIT: As of FY2026 Q2, the actual value is USD 38.48 M. ### Second Quarter 2026 Financial Results #### Revenue ACADIA Pharmaceuticals Inc. reported GAAP total revenues of $308 million for the second quarter of 2026, an increase of 16% compared to $265 million in the second quarter of 2025. Non-GAAP adjusted total revenues were $308 million, up 17% from $262 million in the second quarter of 2025. GAAP net product sales of NUPLAZID were $183 million, a 9% increase from $168 million in the prior year period. Non-GAAP adjusted net product sales of NUPLAZID were $183 million, up 10% from $166 million in the second quarter of 2025. Net product sales of DAYBUE increased by 30% to $125 million, compared to $96 million for the second quarter of 2025. #### Operating Expenses Cost of product sales for the second quarter of 2026 was $28,316 thousand, up from $20,734 thousand for the same period in 2025. Research and development expenses were $81,555 thousand, compared to $77,951 thousand in the second quarter of 2025. Selling, general and administrative expenses reached $160,252 thousand, an increase from $133,507 thousand for the same period in 2025. Total operating expenses for the second quarter of 2026 were $270,123 thousand, compared to $232,192 thousand in the second quarter of 2025. #### Profitability Net income for the second quarter of 2026 was $31,500 thousand, an increase from $26,666 thousand for the same period in 2025. Income from operations was $37,836 thousand, up from $32,374 thousand in the second quarter of 2025. Income before income taxes was $46,473 thousand, compared to $40,211 thousand for the second quarter of 2025. Income tax expense was $14,973 thousand, versus $13,545 thousand in the prior year. Net interest income was $7,990 thousand, an increase from $7,243 thousand for the same period in 2025. Other income was $647 thousand, compared to $594 thousand in the second quarter of 2025. ### Six Months Ended June 30, 2026 Financial Results #### Revenue Total revenues for the six months ended June 30, 2026, were $576,021 thousand, compared to $508,882 thousand for the same period in 2025. #### Operating Expenses Cost of product sales for the six months ended June 30, 2026, was $53,107 thousand, compared to $41,126 thousand for the same period in 2025. Research and development expenses were $158,423 thousand, up from $156,216 thousand for the first half of 2025. Selling, general and administrative expenses totaled $331,271 thousand, compared to $259,877 thousand for the same period in 2025. Total operating expenses for the six months ended June 30, 2026, were $542,801 thousand, compared to $457,219 thousand for the same period in 2025. #### Profitability Net income for the six months ended June 30, 2026, was $35,137 thousand, decreasing from $45,653 thousand for the same period in 2025. Income from operations was $33,220 thousand, compared to $51,663 thousand for the first half of 2025. Income before income taxes was $50,454 thousand, down from $67,990 thousand for the same period in 2025. Income tax expense was $15,317 thousand, compared to $22,337 thousand in the prior year period. Net interest income was $16,045 thousand, an increase from $15,144 thousand for the same period in 2025. Other income was $1,189 thousand, compared to $1,183 thousand for the first half of 2025. #### Cash and Investments ACADIA Pharmaceuticals Inc.’s cash, cash equivalents, and investment securities totaled $956 million at June 30, 2026, an increase from $820 million at December 31, 2025. ### Full Year 2026 Financial Guidance (GAAP) ACADIA Pharmaceuticals Inc. updated its full-year 2026 total revenue guidance to a range of $1.24 billion to $1.30 billion, an increase from the previous range of $1.22 billion to $1.28 billion. NUPLAZID net product sales are reaffirmed in the range of $760 million to $790 million, while DAYBUE global net product sales guidance was raised to $480 million to $510 million from the previous $460 million to $490 million. Research and development expenses are projected to be between $355 million and $380 million, reduced from prior guidance, and selling, general and administrative expenses are expected to be in the range of $660 million to $700 million. ### Related Stocks - [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md) ## Related News & Research - [GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD](https://longbridge.com/en/news/296084900.md) - [ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data](https://longbridge.com/en/news/295699458.md) - [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md) - [ZTO Express Q2 2026 Earnings Preview](https://longbridge.com/en/news/296149351.md) - [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**